Himmelfarb Health Sciences Library, The George Washington University Health Sciences Research Commons

GW Infectious Disease Updates

GW Covid-19 Collection

5-28-2020

Covid-19 Clinical Update 5/28/2020

George Washington University

Follow this and additional works at: https://hsrc.himmelfarb.gwu.edu/infectiousdiseaseupdates

Recommended Citation

George Washington University, "Covid-19 Clinical Update 5/28/2020" (2020). *GW Infectious Disease Updates*. Paper 12. https://hsrc.himmelfarb.gwu.edu/infectiousdiseaseupdates/12

This Presentation is brought to you for free and open access by the GW Covid-19 Collection at Health Sciences Research Commons. It has been accepted for inclusion in GW Infectious Disease Updates by an authorized administrator of Health Sciences Research Commons. For more information, please contact hsrc@gwu.edu.




- 4. TREATMENT
- 5. GW UPDATES

COVID-19 UPDATE

HANA AKSELROD, MD, MPH GW DIVISION OF INFECTIOUS DISEASES 5/28/2020





https://www.popville.com/2020/05/expect-the-unexpected-in-coronaville/ https://www.cdc.gov/coronavirus/2019-ncov/community/rodents.html

Disclosures

- No financial COI
- Pre-print/investigational information discussed
- DC resident





TRENDING

Monting Roundup: Pentago Considers Pentagont Teleworking For Some Staff



MARC 12 1279 PM "Stay-Ad-Home Life", After Two: Month Shuldown, D.C. Will Start Gradual Reopening On Fridey

We Read The City's 80-Page Report About How To Reopen D.C. So You Don't



"Show me a plague, and I'll show you the world!" -- Larry Kramer (1935-2020)

https://www.nytimes.com/2020/03/28/nyregion/coronavirus-larry-kramer-aids.html


Known coronavirus deaths and cases in D.C., Maryland and Virginia

There are a total of 4,118 deaths and 97,078 cases confirmed in the region.



By Rebecca Tan, Fenit Nirappil, Kevin Uhrmacher, Gabriel Florit and Danielle Rindler Updated May 27 at 10:15 a.m.

New daily deaths reported in D.C., Maryland and Virginia



On Friday, May 29, 2020, the District's Stay-at-Home Order will be lifted.

The Public Health Emergency is still in effect and gatherings of more than 10 people are still prohibited.

May 27, 2020

CORONAVIRUS.DC.GOV





Transmission Updates

🔳 Erin Bromage 🛥 🔸 May é 🔹 12 min read

The Risks Know Them Avoid Them

Updated: May 20

Please read this link to learn about the author and background to these posts,

It seems many people are breathing some relief, and I'm not sure why. An epidemic curve has a relatively predictable upslope and once the peak is reached, the back slope can also be predicted. We have robust data from the outbreaks in China and Italy, that shows the backside of the mortality curve declines slowly, with deaths persisting for months. Assuming we have just crested in deaths at 70k, it is possible that we lose another 70,000 people over the next 6 weeks as we come off that peak. That's what's going to happen with a lockdown.


As states reopen, and we give the virus more fuel, all bets are off. I understand the reasons for reopening the economy, but I've said before, if you don't solve the biology, the economy won't recover.

https://www.erinbromage.com/post/the-risks-know-them-avoid-them

Masks reduce airborne transmission

Infectious aerosol particles can be released during breathing and speaking by asymptomatic infected individuals. No masking maximizes exposure, whereas universal masking results in the least exposure.


Particle size (µm) 100 10 1 0.1



GRAPHIC: V. ALTOUNIAN/SCIENCE

Prather KA, et al. Reducing transmission of SARS-CoV-2. *Science*. 2020.

https://science.sciencemag.org/content/ early/2020/05/27/science.abc6197



Lu J, et al. COVID-19 outbreak associated with air conditioning in restaurant, Guangzhou, China, 2020. *Emerg Infect Dis.* 2020.

	Log in
BREF REPORT ARTICLES IN PRESS The effect of state-level stay-at-home orders on 19 infection rates Renan C. Castilo, PhD X © +Elena D. Staguhn, BS © +Elias Weston-Farber, BS © Published. May 24, 2020 + DOI: https://doi.org/10.1016/j.a/e.2020.05.017	POF 1642 KEI COVID-

Highlights
 We examined the effect of state-level stay-at-home orders on COVID-19 diagnoses.
0.113/day pre-order vs. 0.047/day post-order
stay-al-home orders.

Highlights Abstract

Keywords

Background

Mehode

Results

Discussion

Conclusions

Symptomatic vs. Asymptomatic Infection

- 78 patients from 26 transmission cluster series
- Wuhan, China, 12/24/2019-2/24/2020
- Asymptomatic patients were:
 - Younger, 37 [26-45] vs. 56 [34-63] y/o
 - More women, 66.7% vs 31.%
 - Lower rate of abnormal LFTs, 3% vs. 20%
 - Higher CD4 count during recovery, 719 [538-963] vs. 474 [354-811]
 - Faster CT improvement, 9 vs. 15 days
 - Shorter duration of viral shedding by NP swab RT-PCR, 8 [3-12] vs. 19 [16-24] days

Research Letter | Infectious Diseases

May 27, 2020

Comparison of Clinical Characteristics of Patients with Asymptomatic vs Symptomatic Coronavirus Disease 2019 in Wuhan, China

Rongrong Yang, PhD¹; Xlen Gul, MBBS¹; Yong Xlong, PhD¹

≫ Author Affiliations | Article Information


JAMA Netw Open. 2020;3(5):e2010182. doi:10.1001/jamanetworkopen.2020.10182

ORIGINAL ARTICLE

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

Maximilian Ackermann, M.D., Stijn E. Verleden, Ph.D., Mark Kuehnel, Ph.D., Axel Haverich, M.D., Tobias Welte, M.D., Florian Laenger, M.D., Arno Vanstapel, Ph.D., Christopher Werlein, M.D., Helge Stark, Ph.D., Alexandar Tzankov, M.D., William W. Li, M.D., Vincent W. Li, M.D., <u>et al.</u>


- Distinctive vascular features, severe endothelial injury associated with the presence of intracellular virus and disrupted cell membranes
- Alveolar capillary microthrombi were 9 times as prevalent in patients with Covid-19 as in patients with influenza (P<0.001)
- The amount of new vessel growth predominantly intussusceptive angiogenesis — was 2.7 times as high as that in the lungs from patients with influenza (P<0.001)



Annals of the American Thoracic Society

Home > Annals of the American Thoracic Society > List of Issues > Just Accepted

Subphenotyping ARDS in COVID-19 Patients: Consequences for Ventilator Management



medR_χiv

BMJ Yale

Search

THE PREPRINT SERVER FOR HEALTH SCIENC

.

HOME

Early Corticosteroids?

- Quasi-experiment design
- Multi-center health system in Michigan, March 2020
- Adult patients with confirmed moderate-severe COVID
- 81 (38%) got no steroids; 132 (62%) got steroids
 - Methylprednisolone 0.5-1 mg/kg/day x 3 days
- Composite endpoint of escalation of care from ward to ICU, new requirement for ventilation, and mortality
- Composite endpoint observed in 34.9% of steroids group vs. 54.3% of no-steroids group (p=0.005)
 - Treatment effect observed within each component
- LOS lower in steroids group, 8 vs. 5 days (p < 0.001)
- Multivariate regression demonstrated independent reduction in composite endpoint at 14-days (aOR: 0.45; 95% CI [0.25-0.81]).

O Comment on this pape

Early Short Course Corticosteroids in Hospitalized Patients with COVID-19

Raef Fadel, Austin Morrison, Amit Vahia, Zachary R. Smith, Zohra Chaudhry, Pallavi Bhargava, Joseph Miller, Rachel Kenney, George Alangaden, () Mayur S. Ramesh, Henry Ford COVID-19 Management Task Force doi: https://doi.org/10.1101/2020.05.04.20074609

This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.

Treatment	Total (n=213)	Pre-Protocol (n=81)	Post-Protocol (n=132)	p-value
Antimicrobials				
Empiric antibiotic prescribed for pneumonia – no. (%)	163 (76.5)	65 (80.2)	98 (74)	0.316
Median time to empiric antibiotics (IQR) – days	1 (0-1)	1 (0-1)	0 (0-1)	0.631
Median duration of antimicrobials (IQR) - days	4 (2-5)	5 (3-5)	3 (2-5)	0.009
Hydroxychloroquine use - no. (%)	161 (75.6)	57 (70.4)	104 (78.8)	0.167
Median time to hydroxychloroquine initiation (IQR) - days	2 (1-3)	3 (1-4)	1 (0-2)	0.126
Lopinavir/ritonavir and ribavirin use - no. (%)	10 (4.7)	9 (11.1)	1 (0.76)	0.001
Remdesivir use - no. (%)	5 (2.3)	5 (6.2)	0(0)	0.004
Tocilizumab use - no. (%)	14 (6.6)	8 (10.1)	6 (4.5)	0.126
Corticosteroid treatment				
Corticosteroids received at any time - no. (%)	136 (63.8)	46 (56.8)	90 (68.2)	0.094
Corticosteroids received in first 48 hours - no. (%)	65 (30.5)	10 (12.4)	55 (41.7)	< 0.001
Median time to steroid initiation from admission (IQR) - days	2 (1-4)	5 (3-7)	2 (1-3)	< 0.001
Median methylprednisolone dose (IQR) - mg	40 (40-50)	40 (40-50)	40 (35-50)	0.851
Median duration of corticosteroids (IQR) - days	3 (3-3)	3 (3-3)	3 (3-3)	0.812

*IQR denotes Interquartile range

ORIGINAL ARTICLE


Remdesivir for the Treatment of Covid-19 — Preliminary Report

Remdesivir


John H. Beigel, M.D., Kay M. Tomashek, M.D., M.P.H., Lori E. Dodd, Ph.D., Aneesh K. Mehta, M.D., Barry S. Zingman, M.D., Andre C. Kalil, M.D., M.P.H., Elizabeth Hohmann, M.D., Helen Y. Chu, M.D., M.P.H., Annie Luetkemeyer, M.D., Susan Kline, M.D., M.P.H., Diego Lopez de Castilla, M.D., M.P.H., Robert W. Finberg, M.D., <u>et al.</u>, for the ACTT-1 Study Group Members^{*}

- Double-blind RCT, enrolled 2/2020-4/2020 across trial sites in US (45), EU (17), UK (5), Asia (4), Mexico (2)
- 10-day course of IV remdesivir (200 mg LD + 100 mg daily)
- Preliminary results from 1059 patients (538 assigned to remdesivir and 521 to placebo)
- In remdesivir group:
 - Recovery time 11 days (95% Cl, 9 to 12) vs. 15 days (13 to 19); rate ratio for recovery, 1.32; 95% Cl, 1.12 to 1.55)
 - Mortality at 14 days was 7.1% with remdesivir and 11.9% with placebo (HR, 0.70; 95% Cl, 0.47 to 1.04)
 - SAEs reported for 21.1% in remdesivir group vs. 27.0% in placebo group
- Outcomes differed by subgroup and by severity of disease (next slides)
- Acute respiratory failure, hypotension, viral pneumonia, and AKI (~7%) slightly more common in placebo group
- No deaths were considered to be related to treatment assignment
- Limitations:
 - Patients with impaired renal function were excluded from enrollment

Subgroup	No. of Patients	Recovery R	ate Ratio (95% CI)	
All patients	1059	·		1.32 (1.12-1.55)
Geographic region				
North America	844			1.33 (1.11-1.59)
Europe	163	⊢ ¦ ●		1.40 (0.90-2.16)
Asia	52	⊢		1.20 (0.65-2.22)
Race				
White	563	· · · · ·	4	1.39 (1.12-1.73)
Black	219	⊢ <u>;</u> • – – ,		1.14 (0.81-1.61)
Asian	134	⊢		1.04 (0.68-1.57)
Other	143	· · · · · · · · · · · · · · · · · · ·		1.89 (1.15-3.10)
Ethnic group				
Hispanic or Latino	247	⊢ <u>¦</u> ●	4	1.23 (0.88-1.72)
Not Hispanic or Latino	748	·→		1.33 (1.10-1.61)
Age				
18 to <40 yr	119		• · · · · · · · · · · · · · · · · · · ·	2.03 (1.31-3.15)
40 to <65 yr	558	⊢¦ ●		1.16 (0.94-1.44)
≥65 yr	382	•		1.37 (1.02-1.83)
Sex				
Male	682	· · · · · · · · · · · · · · · · · · ·		1.31 (1.07–1.59)
Female	377	¦ •		1.38 (1.05-1.81)
Symptoms duration				
≤10 days	664	¦ ⊢+		1.28 (1.05-1.57)
>10 days	380			1.38 (1.05-1.81)
Baseline ordinal score				
4 (not receiving oxygen)	127	•		1.38 (0.94-2.03)
5 (receiving oxygen)	421	¦ ⊢●		1.47 (1.17–1.84)
 6 (receiving high-flow oxygen or noninvasive mechanical ventilation) 	197	►		1.20 (0.79–1.81)
7 (receiving mechanical ventilation or ECMO)	272	· · · · · · · · · · · · · · · · · · ·	2.0 3.0 4.0	0.95 (0.64–1.42)
		Placebo Better Re	emdesivir Better	



E Patients Receiving Mechanical Ventilation or ECMO



Hydroxychloroquine

- Multinational registry analysis, 671 hospitals, 6 continents
- Patients hospitalized with laboratory-confirmed SARS-CoV-2, 12/2019-4/2020
- Four treatment groups (CQ, CQ + macrolide, HCQ, HCQ + macrolide) and control group (standard care)
 - Excluded patients who started treatment >48 hours after diagnosis or while on mechanical ventilation
 - Excluded patients who also received remdesivir
- Analysis controlled for age, sex, race/ethnicity, BMI, co-morbidities, baseline severity of disease
- In-hospital mortality:
 - Control (9·3%), HCQ (18·0%; HR 1·335), HCQ/M (23·8%; 1·447), CQ (16·4%; 1·365), CQ/M (22·2%; 1·368)
- Clinically significant ventricular arrhythmias:
 - Control (0.3%), HCQ (6.1%; 2.369), HCQ/M (8.1%; 5.106), CQ (4.3%; 3.561), CQ/M (6.5%; 4.011)
- "We were unable to confirm a benefit of hydroxychloroquine or chloroquine, when used alone or with a macrolide, on in-hospital outcomes for COVID-19. Each of these drug regimens was associated with decreased in-hospital survival and an increased frequency of ventricular arrhythmias when used for treatment of COVID-19."

THE LANCET

ARTICLES | ONLINE FIRST

Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis Prof Mandeep R Mehra, MD $\$ \square Sapan S Desai, MD $\$ Prof Frank Ruschitzka, MD $\$ Amit N Patel, MD Published: May 22, 2020 $\$ DOI: https://doi.org/10.1016/S0140-6736(20)31180-6 $\$ Check for updates



GW Updates

- Data analysis on hospitalized patients: Shant Ayanian, Juan Reyes
- COVID-19 Specimen Bank study enrolling patients: Adrienne Poon, Aileen Chang
- COVID-19 Intelligence Unit Brief on Serologic Testing
- COVID-19 Virtual Elective for MS3/MS4 students by GW SMHS Clinical Public Health Group
- Got a COVID-19 publication?

